Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 1

Interventions

pembrolizumab 606Cyclophosphamide 546Magnetic Resonance Spectroscopy 527Radiotherapy 514Specimen Handling 506Nivolumab 412Cisplatin 381Carboplatin 369Biopsy 306Blood Specimen Collection 304Radiosurgery 290Paclitaxel 281Gemcitabine 271Surveys and Questionnaires 270Standard of Care 267Drug Therapy 264fludarabine 263Dexamethasone 263Bevacizumab 253venetoclax 251Oxaliplatin 209Capecitabine 201Rituximab 199Radiation 192Fluorouracil 189Ipilimumab 188durvalumab 185Doxorubicin 179Etoposide 177atezolizumab 175

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × LFB-R603 × 1 year × Clear all
NCT04624633 2026-02-25

Acalabrutinib, Umbralisib, and Ublituximab (AU2) In Relapsed and Untreated CLL

Dana-Farber Cancer Institute

Phase 2 Active not recruiting
29 enrolled 9 charts
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡